SHR3680 + goserelin

SHR3680 + goserelin is a combination therapy under investigation primarily for the treatment of prostate cancer. **SHR3680** is a non-steroidal, selective androgen receptor antagonist, while **goserelin** is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH/GnRH agonist) that suppresses gonadal steroid production. SHR3680 directly blocks androgen receptor signaling to inhibit tumor growth, and goserelin reduces production of testosterone by downregulating pituitary gonadotropins, leading to castrate levels of testosterone[7][5][2]. The combination aims at both androgen deprivation (chemical castration) and direct androgen receptor blockade, thereby more effectively inhibiting androgen-driven tumor cell growth, especially in prostate cancer.

Brand names

Zoladex

Other names

goserelingoserelin acetate